NCT06106074View on ClinicalTrials.gov

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Tolebrutinib

Tablet, oral

DRUG

Placebo

Tablet, oral

Trial Locations (1)

37920

New Orleans Clinical Research Site Number : 8400001, Knoxville

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06106074 - Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants | Biotech Hunter | Biotech Hunter